Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5902.074 | 0.9959 | 0.9936 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5902.074 | 0.9959 | 0.9936 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5902.074 | 1.0476 | 1.0732 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5902.074 | 1.0476 | 1.0732 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5902.074 | 0.9983 | 0.9973 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5902.074 | 0.9983 | 0.9973 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5902.074 | 1.0401 | 1.0617 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5902.074 | 1.0401 | 1.0617 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5902.074 | 0.5381 | 0.2389 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5902.074 | 0.5381 | 0.2389 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5902.074 | 0.1220 | -0.6065 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5902.074 | 0.1220 | -0.6065 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5902.074 | 0.0569 | -0.7818 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5902.074 | 0.0569 | -0.7818 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5902.074 | 0.0601 | -0.7723 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5902.074 | 0.0601 | -0.7723 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5902.074 | 0.0579 | -0.7789 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5902.074 | 0.0579 | -0.7789 | 1.2939 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5903.074 | 0.9910 | 0.9832 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5903.074 | 0.9910 | 0.9832 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5903.074 | 0.9909 | 0.9830 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5903.074 | 0.9909 | 0.9830 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5903.074 | 1.0312 | 1.0581 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5903.074 | 1.0312 | 1.0581 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5903.074 | 1.0341 | 1.0636 | 1.0729 |